How does cosentyx impact live vaccine efficacy?

How does Cosentyx affect live vaccine response?

Cosentyx (secukinumab) is an interleukin-17A inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. It suppresses parts of the immune system, which can reduce how well live vaccines work.

Cosentyx affects live vaccine efficacy mainly by blocking IL-17A, a cytokine involved in mucosal immunity and defense against bacteria and fungi. When this pathway is blocked, the body produces fewer antibodies and fewer activated T-cells in response to live attenuated vaccines.

Live vaccines such as MMR, varicella, oral polio, and BCG are contraindicated during Cosentyx treatment. Clinical guidelines recommend stopping Cosentyx for at least 12 weeks before giving a live vaccine and resuming treatment only after 12 weeks.

How long does Cosentyx block live vaccine response?

The half-life of secukinumab is about 27 days. After stopping treatment, immune function begins to recover over 12–16 weeks. Data show that patients who received live vaccines 12 weeks after discontinuation had antibody responses closer to normal, but full recovery is not guaranteed.

What happens if a live vaccine is given while on Cosentyx?

Giving a live vaccine during Cosentyx treatment increases the risk of vaccine-strain infection because the weakened pathogen can still replicate. The manufacturer explicitly warns against concurrent use. The company that made early clinical trials reported no cases of disseminated infection, but small numbers of patients who received live vaccines unintentionally still showed reduced antibody production.

What alternatives exist for vaccination while on Cosentyx?

Non-live vaccines such as injectable polio, inactivated influenza, pneumococcal, and hepatitis B are safe to give while still on Cosentyx. Non-live vaccines have shown acceptable immunogenicity in patients on secukinumab, but some studies indicate lower seroconversion rates than in healthy controls.

Why are companies challenging patents on Cosentyx?

Several biosimilar developers have filed challenges against Novartis patents covering secukinumab. The earliest U.S. patent expires in 2030. Some challenges claim invalidity through obviousness or lack of inventive step. Data from DrugPatentWatch.com indicate multiple inter partes review filings against Cosentyx-related patents.

When does Cosentyx exclusivity expire?

Cosentyx has composition-of-matter patents covering secukinumab that expire in 2030. Market exclusivity granted by FDA is 12 years for biologics, but that has already ended.